Improve walking with Parkinson medication
- Trial ID
- NCT02994719
- Official Title
- Gait Pattern Analysis in Neurological Disease
- Goal
- Improve walking with Parkinson medication
- Status
- RECRUITING
- Sponsor
- Beth Israel Deaconess Medical Center
- Study Type
- OBSERVATIONAL
- Enrollment
- 120 participants
- Conditions
- Parkinson's Disease, Parkinsonian Disorders, Atypical Parkinson Disease, Progressive Supranuclear Palsy, Multiple System Atrophy, Corticobasal Degeneration, Gait, Frontal, Huntington Disease
- Interventions
- Anti-Parkinson medication, Deep Brain Stimulation
Plain-Language Summary
The goal is to map how Parkinson's and related disorders change walking, and to measure how anti-Parkinson medications and deep brain stimulation alter gait compared with healthy adults. Participants have their walking recorded while on their usual anti-Parkinson meds, which raise brain dopamine to improve movement, and for those with DBS the team may compare gait with stimulation on versus off, using motion analysis and sensors to quantify stride, speed, variability, and frontal gait features. Adults 18 to 85 are eligible, including people with Parkinson's or atypical parkinsonism who have at least two cardinal motor signs and healthy controls without walking complaints, with requirements for cognitive screening, safe mobility, and exclusions for other causes of parkinsonism, recent hospitalization, serious heart or lung disease, or participation in another interventional trial.
Locations
- Clinical Research Center BIDMC, Boston, Massachusetts, United States
Frequently Asked Questions
- What is this trial testing?
- This trial is studying Anti-Parkinson medication. The goal is to map how Parkinson's and related disorders change walking, and to measure how anti-Parkinson medications and deep brain stimulation alter gait compared with healthy adults. Participants have their walking recorded while on their usual anti-Parkinson meds, which raise brain dopamine to improve movement, and for those with DBS the team may compare gait with stimulation on versus off, using motion analysis and sensors to quantify stride, speed, variability, and frontal gait features. Adults 18 to 85 are eligible, including people with Parkinson's or atypical parkinsonism who have at least two cardinal motor signs and healthy controls without walking complaints, with requirements for cognitive screening, safe mobility, and exclusions for other causes of parkinsonism, recent hospitalization, serious heart or lung disease, or participation in another interventional trial.
- Who can participate?
- Participants must be between 18 Years and 85 Years.
- Where is this trial located?
- This trial is recruiting at 1 location.
- Does it cost anything to join?
- No. There is no cost to participate. Study-related care and treatment are provided at no charge.
- How long does the trial last?
- This trial is estimated to last approximately 10 years and 4 months.